Amrapali Industries Limited (AMRAPLIN.BO) Stock Competitors & Peer Comparison
See (AMRAPLIN.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Software - Application Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMRAPLIN.BO | ₹42.31 | -0.77% | 2.2B | 17.27 | ₹2.45 | N/A |
| TATAELXSI.NS | ₹4,065.50 | -1.23% | 253.3B | 40.28 | ₹100.92 | +1.84% |
| TATAELXSI.BO | ₹4,063.60 | -1.26% | 252.6B | 43.57 | ₹93.27 | +1.84% |
| BBOX.NS | ₹1,023.00 | -1.82% | 181.7B | 80.49 | ₹12.71 | +0.10% |
| BBOX.BO | ₹1,022.85 | -1.72% | 181.7B | 80.48 | ₹12.71 | +0.10% |
| KFINTECH.BO | ₹916.45 | +1.07% | 158.2B | 45.62 | ₹20.09 | +0.82% |
| KFINTECH.NS | ₹915.35 | +0.94% | 158B | 45.59 | ₹20.08 | +0.82% |
| BLACKBUCK.NS | ₹574.05 | +4.31% | 104.5B | 65.38 | ₹8.78 | N/A |
| INTELLECT.NS | ₹746.70 | -1.40% | 103.8B | 30.72 | ₹24.31 | +0.94% |
| INTELLECT.BO | ₹747.10 | -1.15% | 103.8B | 30.71 | ₹24.33 | +0.94% |
Stock Comparison
AMRAPLIN.BO vs TATAELXSI.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TATAELXSI.NS has a market cap of 253.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TATAELXSI.NS trades at ₹4,065.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TATAELXSI.NS's P/E ratio is 40.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TATAELXSI.NS's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TATAELXSI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TATAELXSI.NS's competition here
AMRAPLIN.BO vs TATAELXSI.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TATAELXSI.BO has a market cap of 252.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TATAELXSI.BO trades at ₹4,063.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TATAELXSI.BO's P/E ratio is 43.57. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TATAELXSI.BO's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TATAELXSI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TATAELXSI.BO's competition here
AMRAPLIN.BO vs BBOX.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, BBOX.NS has a market cap of 181.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while BBOX.NS trades at ₹1,023.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas BBOX.NS's P/E ratio is 80.49. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to BBOX.NS's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BBOX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BBOX.NS's competition here
AMRAPLIN.BO vs BBOX.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, BBOX.BO has a market cap of 181.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while BBOX.BO trades at ₹1,022.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas BBOX.BO's P/E ratio is 80.48. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to BBOX.BO's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BBOX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BBOX.BO's competition here
AMRAPLIN.BO vs KFINTECH.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KFINTECH.BO has a market cap of 158.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KFINTECH.BO trades at ₹916.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KFINTECH.BO's P/E ratio is 45.62. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KFINTECH.BO's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KFINTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KFINTECH.BO's competition here
AMRAPLIN.BO vs KFINTECH.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KFINTECH.NS has a market cap of 158B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KFINTECH.NS trades at ₹915.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KFINTECH.NS's P/E ratio is 45.59. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KFINTECH.NS's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KFINTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KFINTECH.NS's competition here
AMRAPLIN.BO vs BLACKBUCK.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, BLACKBUCK.NS has a market cap of 104.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while BLACKBUCK.NS trades at ₹574.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas BLACKBUCK.NS's P/E ratio is 65.38. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to BLACKBUCK.NS's ROE of +0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BLACKBUCK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BLACKBUCK.NS's competition here
AMRAPLIN.BO vs INTELLECT.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, INTELLECT.NS has a market cap of 103.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while INTELLECT.NS trades at ₹746.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas INTELLECT.NS's P/E ratio is 30.72. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to INTELLECT.NS's ROE of +0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INTELLECT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INTELLECT.NS's competition here
AMRAPLIN.BO vs INTELLECT.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, INTELLECT.BO has a market cap of 103.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while INTELLECT.BO trades at ₹747.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas INTELLECT.BO's P/E ratio is 30.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to INTELLECT.BO's ROE of +0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INTELLECT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INTELLECT.BO's competition here
AMRAPLIN.BO vs RATEGAIN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RATEGAIN.BO has a market cap of 102.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RATEGAIN.BO trades at ₹869.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RATEGAIN.BO's P/E ratio is 53.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RATEGAIN.BO's ROE of +0.11%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RATEGAIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RATEGAIN.BO's competition here
AMRAPLIN.BO vs RATEGAIN.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RATEGAIN.NS has a market cap of 102.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RATEGAIN.NS trades at ₹867.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RATEGAIN.NS's P/E ratio is 52.72. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RATEGAIN.NS's ROE of +0.11%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RATEGAIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RATEGAIN.NS's competition here
AMRAPLIN.BO vs TANLA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TANLA.NS has a market cap of 69.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TANLA.NS trades at ₹521.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TANLA.NS's P/E ratio is 13.63. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TANLA.NS's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TANLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TANLA.NS's competition here
AMRAPLIN.BO vs TANLA.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TANLA.BO has a market cap of 69.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TANLA.BO trades at ₹520.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TANLA.BO's P/E ratio is 13.63. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TANLA.BO's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TANLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TANLA.BO's competition here
AMRAPLIN.BO vs NEWGEN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NEWGEN.BO has a market cap of 68.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NEWGEN.BO trades at ₹482.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NEWGEN.BO's P/E ratio is 22.89. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NEWGEN.BO's ROE of +0.19%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NEWGEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NEWGEN.BO's competition here
AMRAPLIN.BO vs NEWGEN.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NEWGEN.NS has a market cap of 68B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NEWGEN.NS trades at ₹481.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NEWGEN.NS's P/E ratio is 22.86. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NEWGEN.NS's ROE of +0.19%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NEWGEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NEWGEN.NS's competition here
AMRAPLIN.BO vs MAPMYINDIA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MAPMYINDIA.NS has a market cap of 48.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MAPMYINDIA.NS trades at ₹889.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MAPMYINDIA.NS's P/E ratio is 36.36. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MAPMYINDIA.NS's ROE of +0.16%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MAPMYINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MAPMYINDIA.NS's competition here
AMRAPLIN.BO vs MAPMYINDIA.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MAPMYINDIA.BO has a market cap of 48.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MAPMYINDIA.BO trades at ₹888.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MAPMYINDIA.BO's P/E ratio is 36.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MAPMYINDIA.BO's ROE of +0.16%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MAPMYINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MAPMYINDIA.BO's competition here
AMRAPLIN.BO vs EMUDHRA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, EMUDHRA.NS has a market cap of 37.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while EMUDHRA.NS trades at ₹459.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas EMUDHRA.NS's P/E ratio is 35.37. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to EMUDHRA.NS's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to EMUDHRA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check EMUDHRA.NS's competition here
AMRAPLIN.BO vs EMUDHRA.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, EMUDHRA.BO has a market cap of 37.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while EMUDHRA.BO trades at ₹460.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas EMUDHRA.BO's P/E ratio is 35.40. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to EMUDHRA.BO's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to EMUDHRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check EMUDHRA.BO's competition here
AMRAPLIN.BO vs KERNEX.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KERNEX.NS has a market cap of 33.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KERNEX.NS trades at ₹1,999.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KERNEX.NS's P/E ratio is 38.01. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KERNEX.NS's ROE of +0.48%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KERNEX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KERNEX.NS's competition here
AMRAPLIN.BO vs KERNEX.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KERNEX.BO has a market cap of 33.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KERNEX.BO trades at ₹1,997.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KERNEX.BO's P/E ratio is 62.27. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KERNEX.BO's ROE of +0.48%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KERNEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KERNEX.BO's competition here
AMRAPLIN.BO vs NPST.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NPST.NS has a market cap of 32.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NPST.NS trades at ₹1,572.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NPST.NS's P/E ratio is 76.50. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NPST.NS's ROE of +0.15%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NPST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NPST.NS's competition here
AMRAPLIN.BO vs RAMCOSYS.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RAMCOSYS.NS has a market cap of 20.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RAMCOSYS.NS trades at ₹557.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RAMCOSYS.NS's P/E ratio is 50.06. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RAMCOSYS.NS's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMCOSYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMCOSYS.NS's competition here
AMRAPLIN.BO vs RAMCOSYS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RAMCOSYS.BO has a market cap of 20.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RAMCOSYS.BO trades at ₹557.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RAMCOSYS.BO's P/E ratio is 50.08. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RAMCOSYS.BO's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMCOSYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMCOSYS.BO's competition here
AMRAPLIN.BO vs NUCLEUS.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NUCLEUS.NS has a market cap of 20.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NUCLEUS.NS trades at ₹785.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NUCLEUS.NS's P/E ratio is 17.80. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NUCLEUS.NS's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NUCLEUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NUCLEUS.NS's competition here
AMRAPLIN.BO vs NUCLEUS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NUCLEUS.BO has a market cap of 20.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NUCLEUS.BO trades at ₹785.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NUCLEUS.BO's P/E ratio is 17.69. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NUCLEUS.BO's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NUCLEUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NUCLEUS.BO's competition here
AMRAPLIN.BO vs IZMO.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, IZMO.NS has a market cap of 16.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while IZMO.NS trades at ₹1,075.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas IZMO.NS's P/E ratio is 33.78. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to IZMO.NS's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IZMO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IZMO.NS's competition here
AMRAPLIN.BO vs IZMO.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, IZMO.BO has a market cap of 16B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while IZMO.BO trades at ₹1,076.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas IZMO.BO's P/E ratio is 33.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to IZMO.BO's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IZMO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IZMO.BO's competition here
AMRAPLIN.BO vs GENESYS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, GENESYS.BO has a market cap of 14.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while GENESYS.BO trades at ₹352.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas GENESYS.BO's P/E ratio is 24.21. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to GENESYS.BO's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to GENESYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check GENESYS.BO's competition here
AMRAPLIN.BO vs GENESYS.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, GENESYS.NS has a market cap of 14.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while GENESYS.NS trades at ₹350.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas GENESYS.NS's P/E ratio is 44.29. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to GENESYS.NS's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to GENESYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check GENESYS.NS's competition here
AMRAPLIN.BO vs KODYTECH.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KODYTECH.NS has a market cap of 14.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KODYTECH.NS trades at ₹1,117.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KODYTECH.NS's P/E ratio is 90.03. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KODYTECH.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KODYTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KODYTECH.NS's competition here
AMRAPLIN.BO vs MEGASOFT.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MEGASOFT.NS has a market cap of 13.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MEGASOFT.NS trades at ₹188.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MEGASOFT.NS's P/E ratio is 7.91. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MEGASOFT.NS's ROE of +0.73%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MEGASOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MEGASOFT.NS's competition here
AMRAPLIN.BO vs UNIECOM.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, UNIECOM.NS has a market cap of 10.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while UNIECOM.NS trades at ₹89.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas UNIECOM.NS's P/E ratio is 50.39. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to UNIECOM.NS's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to UNIECOM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check UNIECOM.NS's competition here
AMRAPLIN.BO vs QUICKHEAL.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, QUICKHEAL.NS has a market cap of 9.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while QUICKHEAL.NS trades at ₹178.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas QUICKHEAL.NS's P/E ratio is -89.94. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to QUICKHEAL.NS's ROE of -0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to QUICKHEAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check QUICKHEAL.NS's competition here
AMRAPLIN.BO vs QUICKHEAL.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, QUICKHEAL.BO has a market cap of 9.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while QUICKHEAL.BO trades at ₹177.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas QUICKHEAL.BO's P/E ratio is -89.17. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to QUICKHEAL.BO's ROE of -0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to QUICKHEAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check QUICKHEAL.BO's competition here
AMRAPLIN.BO vs TAC.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TAC.NS has a market cap of 8.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TAC.NS trades at ₹407.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TAC.NS's P/E ratio is 59.86. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TAC.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TAC.NS's competition here
AMRAPLIN.BO vs VEEFIN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, VEEFIN.BO has a market cap of 8.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while VEEFIN.BO trades at ₹327.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas VEEFIN.BO's P/E ratio is 37.16. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to VEEFIN.BO's ROE of +0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VEEFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VEEFIN.BO's competition here
AMRAPLIN.BO vs KELLTONTEC.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KELLTONTEC.NS has a market cap of 8.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KELLTONTEC.NS trades at ₹15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KELLTONTEC.NS's P/E ratio is 8.69. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KELLTONTEC.NS's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KELLTONTEC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KELLTONTEC.NS's competition here
AMRAPLIN.BO vs KELLTONTEC.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KELLTONTEC.BO has a market cap of 8.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KELLTONTEC.BO trades at ₹15.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KELLTONTEC.BO's P/E ratio is 8.68. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KELLTONTEC.BO's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KELLTONTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KELLTONTEC.BO's competition here
AMRAPLIN.BO vs KSOLVES.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KSOLVES.NS has a market cap of 6.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KSOLVES.NS trades at ₹291.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KSOLVES.NS's P/E ratio is 20.09. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KSOLVES.NS's ROE of +1.32%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KSOLVES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KSOLVES.NS's competition here
AMRAPLIN.BO vs KSOLVES.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KSOLVES.BO has a market cap of 6.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KSOLVES.BO trades at ₹290.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KSOLVES.BO's P/E ratio is 20.10. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KSOLVES.BO's ROE of +1.32%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KSOLVES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KSOLVES.BO's competition here
AMRAPLIN.BO vs INNOVANA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, INNOVANA.NS has a market cap of 6.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while INNOVANA.NS trades at ₹316.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas INNOVANA.NS's P/E ratio is 17.78. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to INNOVANA.NS's ROE of +0.16%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INNOVANA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INNOVANA.NS's competition here
AMRAPLIN.BO vs SUBEXLTD.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SUBEXLTD.NS has a market cap of 6.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SUBEXLTD.NS trades at ₹11.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SUBEXLTD.NS's P/E ratio is 22.47. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SUBEXLTD.NS's ROE of +0.09%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SUBEXLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SUBEXLTD.NS's competition here
AMRAPLIN.BO vs SOFTTECH.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SOFTTECH.NS has a market cap of 5.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SOFTTECH.NS trades at ₹424.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SOFTTECH.NS's P/E ratio is 120.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SOFTTECH.NS's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFTTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFTTECH.NS's competition here
AMRAPLIN.BO vs SOFTTECH.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SOFTTECH.BO has a market cap of 5.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SOFTTECH.BO trades at ₹404.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SOFTTECH.BO's P/E ratio is 113.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SOFTTECH.BO's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFTTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFTTECH.BO's competition here
AMRAPLIN.BO vs IRIS.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, IRIS.NS has a market cap of 5.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while IRIS.NS trades at ₹270.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas IRIS.NS's P/E ratio is 39.72. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to IRIS.NS's ROE of +0.93%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to IRIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IRIS.NS's competition here
AMRAPLIN.BO vs IRIS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, IRIS.BO has a market cap of 5.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while IRIS.BO trades at ₹269.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas IRIS.BO's P/E ratio is 39.54. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to IRIS.BO's ROE of +0.93%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to IRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IRIS.BO's competition here
AMRAPLIN.BO vs DANLAW.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, DANLAW.BO has a market cap of 5.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while DANLAW.BO trades at ₹1,096.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas DANLAW.BO's P/E ratio is 23.21. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to DANLAW.BO's ROE of +0.27%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to DANLAW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check DANLAW.BO's competition here
AMRAPLIN.BO vs ABMKNO.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, ABMKNO.BO has a market cap of 4.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while ABMKNO.BO trades at ₹218.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas ABMKNO.BO's P/E ratio is 44.49. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to ABMKNO.BO's ROE of +0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ABMKNO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ABMKNO.BO's competition here
AMRAPLIN.BO vs INFOBEAN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, INFOBEAN.BO has a market cap of 4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while INFOBEAN.BO trades at ₹166.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas INFOBEAN.BO's P/E ratio is 18.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to INFOBEAN.BO's ROE of +0.24%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INFOBEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INFOBEAN.BO's competition here
AMRAPLIN.BO vs INFOBEAN.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, INFOBEAN.NS has a market cap of 4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while INFOBEAN.NS trades at ₹166.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas INFOBEAN.NS's P/E ratio is 18.70. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to INFOBEAN.NS's ROE of +0.24%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INFOBEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INFOBEAN.NS's competition here
AMRAPLIN.BO vs MOS.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MOS.NS has a market cap of 3.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MOS.NS trades at ₹14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MOS.NS's P/E ratio is 26.27. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MOS.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MOS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MOS.NS's competition here
AMRAPLIN.BO vs XTGLOBAL.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, XTGLOBAL.NS has a market cap of 3.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while XTGLOBAL.NS trades at ₹27.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas XTGLOBAL.NS's P/E ratio is 32.96. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to XTGLOBAL.NS's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to XTGLOBAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check XTGLOBAL.NS's competition here
AMRAPLIN.BO vs SYSTANGO.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SYSTANGO.NS has a market cap of 3.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SYSTANGO.NS trades at ₹233.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SYSTANGO.NS's P/E ratio is 10.61. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SYSTANGO.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SYSTANGO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SYSTANGO.NS's competition here
AMRAPLIN.BO vs TRACXN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TRACXN.BO has a market cap of 3.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TRACXN.BO trades at ₹30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TRACXN.BO's P/E ratio is -42.26. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TRACXN.BO's ROE of -0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRACXN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRACXN.BO's competition here
AMRAPLIN.BO vs TRACXN.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TRACXN.NS has a market cap of 3.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TRACXN.NS trades at ₹30.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TRACXN.NS's P/E ratio is -41.85. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TRACXN.NS's ROE of -0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRACXN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRACXN.NS's competition here
AMRAPLIN.BO vs PROPEQUITY.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, PROPEQUITY.NS has a market cap of 2.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while PROPEQUITY.NS trades at ₹240.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas PROPEQUITY.NS's P/E ratio is 19.32. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to PROPEQUITY.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to PROPEQUITY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check PROPEQUITY.NS's competition here
AMRAPLIN.BO vs VIAANINDUS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, VIAANINDUS.BO has a market cap of 2.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while VIAANINDUS.BO trades at ₹1,940.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas VIAANINDUS.BO's P/E ratio is -250.65. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to VIAANINDUS.BO's ROE of +1.43%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to VIAANINDUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIAANINDUS.BO's competition here
AMRAPLIN.BO vs TREJHARA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TREJHARA.NS has a market cap of 2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TREJHARA.NS trades at ₹140.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TREJHARA.NS's P/E ratio is 38.40. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TREJHARA.NS's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TREJHARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TREJHARA.NS's competition here
AMRAPLIN.BO vs TREJHARA.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TREJHARA.BO has a market cap of 2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TREJHARA.BO trades at ₹140.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TREJHARA.BO's P/E ratio is 38.35. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TREJHARA.BO's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TREJHARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TREJHARA.BO's competition here
AMRAPLIN.BO vs AVANCE.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, AVANCE.BO has a market cap of 1.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while AVANCE.BO trades at ₹0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas AVANCE.BO's P/E ratio is 13.86. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to AVANCE.BO's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AVANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AVANCE.BO's competition here
AMRAPLIN.BO vs VIRINCHI.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, VIRINCHI.BO has a market cap of 1.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while VIRINCHI.BO trades at ₹16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas VIRINCHI.BO's P/E ratio is -6.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to VIRINCHI.BO's ROE of -0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRINCHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRINCHI.BO's competition here
AMRAPLIN.BO vs VIRINCHI.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, VIRINCHI.NS has a market cap of 1.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while VIRINCHI.NS trades at ₹16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas VIRINCHI.NS's P/E ratio is -6.68. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to VIRINCHI.NS's ROE of -0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRINCHI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRINCHI.NS's competition here
AMRAPLIN.BO vs 7SEASL.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, 7SEASL.BO has a market cap of 1.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while 7SEASL.BO trades at ₹78.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas 7SEASL.BO's P/E ratio is 82.07. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to 7SEASL.BO's ROE of +0.09%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to 7SEASL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check 7SEASL.BO's competition here
AMRAPLIN.BO vs CALSOFT.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CALSOFT.NS has a market cap of 1.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CALSOFT.NS trades at ₹25.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CALSOFT.NS's P/E ratio is 141.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CALSOFT.NS's ROE of +0.37%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CALSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CALSOFT.NS's competition here
AMRAPLIN.BO vs CALSOFT.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CALSOFT.BO has a market cap of 1.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CALSOFT.BO trades at ₹25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CALSOFT.BO's P/E ratio is 141.33. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CALSOFT.BO's ROE of +0.37%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CALSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CALSOFT.BO's competition here
AMRAPLIN.BO vs CNIRESLTD.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CNIRESLTD.BO has a market cap of 1.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CNIRESLTD.BO trades at ₹10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CNIRESLTD.BO's P/E ratio is -23.89. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CNIRESLTD.BO's ROE of -0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CNIRESLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CNIRESLTD.BO's competition here
AMRAPLIN.BO vs CURAA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CURAA.NS has a market cap of 993.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CURAA.NS trades at ₹82.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CURAA.NS's P/E ratio is -53.99. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CURAA.NS's ROE of -0.21%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CURAA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CURAA.NS's competition here
AMRAPLIN.BO vs SGLRES.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SGLRES.BO has a market cap of 716.4M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SGLRES.BO trades at ₹2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SGLRES.BO's P/E ratio is 143.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SGLRES.BO's ROE of -0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SGLRES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SGLRES.BO's competition here
AMRAPLIN.BO vs VIRTUALS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, VIRTUALS.BO has a market cap of 691.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while VIRTUALS.BO trades at ₹20.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas VIRTUALS.BO's P/E ratio is -14.77. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to VIRTUALS.BO's ROE of +0.08%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRTUALS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRTUALS.BO's competition here
AMRAPLIN.BO vs SECURKLOUD.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SECURKLOUD.BO has a market cap of 674.7M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SECURKLOUD.BO trades at ₹19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SECURKLOUD.BO's P/E ratio is -0.48. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SECURKLOUD.BO's ROE of -13.95%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SECURKLOUD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SECURKLOUD.BO's competition here
AMRAPLIN.BO vs SECURKLOUD.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SECURKLOUD.NS has a market cap of 646.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SECURKLOUD.NS trades at ₹19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SECURKLOUD.NS's P/E ratio is -0.48. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SECURKLOUD.NS's ROE of -13.95%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SECURKLOUD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SECURKLOUD.NS's competition here
AMRAPLIN.BO vs ODYSSEY.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, ODYSSEY.BO has a market cap of 612.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while ODYSSEY.BO trades at ₹38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas ODYSSEY.BO's P/E ratio is 15.24. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to ODYSSEY.BO's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ODYSSEY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ODYSSEY.BO's competition here
AMRAPLIN.BO vs JUPITERIN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, JUPITERIN.BO has a market cap of 561.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while JUPITERIN.BO trades at ₹54.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas JUPITERIN.BO's P/E ratio is 1120.80. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to JUPITERIN.BO's ROE of -0.06%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to JUPITERIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check JUPITERIN.BO's competition here
AMRAPLIN.BO vs CRANESSOFT.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CRANESSOFT.BO has a market cap of 556.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CRANESSOFT.BO trades at ₹3.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CRANESSOFT.BO's P/E ratio is -2.09. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CRANESSOFT.BO's ROE of +0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CRANESSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CRANESSOFT.BO's competition here
AMRAPLIN.BO vs SOFCOM.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SOFCOM.BO has a market cap of 512.4M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SOFCOM.BO trades at ₹21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SOFCOM.BO's P/E ratio is 92.04. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SOFCOM.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFCOM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFCOM.BO's competition here
AMRAPLIN.BO vs AEONXDIGI.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, AEONXDIGI.BO has a market cap of 496.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while AEONXDIGI.BO trades at ₹107.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas AEONXDIGI.BO's P/E ratio is -79.89. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to AEONXDIGI.BO's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AEONXDIGI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AEONXDIGI.BO's competition here
AMRAPLIN.BO vs SAGARSOFT.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SAGARSOFT.BO has a market cap of 490M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SAGARSOFT.BO trades at ₹76.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SAGARSOFT.BO's P/E ratio is -6.54. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SAGARSOFT.BO's ROE of -0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SAGARSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SAGARSOFT.BO's competition here
AMRAPLIN.BO vs NETLINK.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, NETLINK.BO has a market cap of 486.7M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while NETLINK.BO trades at ₹192.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas NETLINK.BO's P/E ratio is 23.97. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to NETLINK.BO's ROE of +0.06%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NETLINK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NETLINK.BO's competition here
AMRAPLIN.BO vs SAWABUSI.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, SAWABUSI.BO has a market cap of 377.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while SAWABUSI.BO trades at ₹0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas SAWABUSI.BO's P/E ratio is 8.25. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to SAWABUSI.BO's ROE of -0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SAWABUSI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SAWABUSI.BO's competition here
AMRAPLIN.BO vs RAMINFO.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RAMINFO.BO has a market cap of 364.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RAMINFO.BO trades at ₹44.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RAMINFO.BO's P/E ratio is 19.78. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RAMINFO.BO's ROE of +0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMINFO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMINFO.BO's competition here
AMRAPLIN.BO vs HOMESFY.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, HOMESFY.NS has a market cap of 326.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while HOMESFY.NS trades at ₹107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas HOMESFY.NS's P/E ratio is 24.04. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to HOMESFY.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to HOMESFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check HOMESFY.NS's competition here
AMRAPLIN.BO vs TELESYS.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TELESYS.BO has a market cap of 282.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TELESYS.BO trades at ₹13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TELESYS.BO's P/E ratio is N/A. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TELESYS.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TELESYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TELESYS.BO's competition here
AMRAPLIN.BO vs WESTLEIRES.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, WESTLEIRES.BO has a market cap of 275.3M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while WESTLEIRES.BO trades at ₹90.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas WESTLEIRES.BO's P/E ratio is 500.83. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to WESTLEIRES.BO's ROE of +0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to WESTLEIRES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check WESTLEIRES.BO's competition here
AMRAPLIN.BO vs TRIDHYA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TRIDHYA.NS has a market cap of 273.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TRIDHYA.NS trades at ₹11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TRIDHYA.NS's P/E ratio is -7.68. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TRIDHYA.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRIDHYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRIDHYA.NS's competition here
AMRAPLIN.BO vs JUNE.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, JUNE.BO has a market cap of 264.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while JUNE.BO trades at ₹5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas JUNE.BO's P/E ratio is -55.50. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to JUNE.BO's ROE of -0.92%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to JUNE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check JUNE.BO's competition here
AMRAPLIN.BO vs MICROPRO.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MICROPRO.NS has a market cap of 264.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MICROPRO.NS trades at ₹18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MICROPRO.NS's P/E ratio is -11.08. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MICROPRO.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MICROPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MICROPRO.NS's competition here
AMRAPLIN.BO vs YUDIZ.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, YUDIZ.NS has a market cap of 253.3M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while YUDIZ.NS trades at ₹24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas YUDIZ.NS's P/E ratio is -21.92. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to YUDIZ.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to YUDIZ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check YUDIZ.NS's competition here
AMRAPLIN.BO vs KASHYAP.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, KASHYAP.BO has a market cap of 252.4M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while KASHYAP.BO trades at ₹5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas KASHYAP.BO's P/E ratio is -132.25. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to KASHYAP.BO's ROE of -0.30%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KASHYAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KASHYAP.BO's competition here
AMRAPLIN.BO vs AHASOLAR.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, AHASOLAR.BO has a market cap of 242M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while AHASOLAR.BO trades at ₹78.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas AHASOLAR.BO's P/E ratio is 117.16. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to AHASOLAR.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AHASOLAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AHASOLAR.BO's competition here
AMRAPLIN.BO vs ERPSOFT.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, ERPSOFT.BO has a market cap of 237.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while ERPSOFT.BO trades at ₹59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas ERPSOFT.BO's P/E ratio is 130.22. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to ERPSOFT.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ERPSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ERPSOFT.BO's competition here
AMRAPLIN.BO vs TELECANOR.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, TELECANOR.BO has a market cap of 198.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while TELECANOR.BO trades at ₹17.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas TELECANOR.BO's P/E ratio is -51.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to TELECANOR.BO's ROE of -1.77%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TELECANOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TELECANOR.BO's competition here
AMRAPLIN.BO vs RADIOWALLA.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, RADIOWALLA.NS has a market cap of 178.7M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while RADIOWALLA.NS trades at ₹25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas RADIOWALLA.NS's P/E ratio is 26.41. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to RADIOWALLA.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RADIOWALLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RADIOWALLA.NS's competition here
AMRAPLIN.BO vs COSYN.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, COSYN.BO has a market cap of 161.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while COSYN.BO trades at ₹21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas COSYN.BO's P/E ratio is 143.20. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to COSYN.BO's ROE of +0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to COSYN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check COSYN.BO's competition here
AMRAPLIN.BO vs CONTCHM.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, CONTCHM.BO has a market cap of 145.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while CONTCHM.BO trades at ₹64.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas CONTCHM.BO's P/E ratio is 23.33. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to CONTCHM.BO's ROE of +0.09%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CONTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CONTCHM.BO's competition here
AMRAPLIN.BO vs DHTL.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, DHTL.NS has a market cap of 127.3M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while DHTL.NS trades at ₹40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas DHTL.NS's P/E ratio is -6.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to DHTL.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to DHTL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check DHTL.NS's competition here
AMRAPLIN.BO vs OTCO.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, OTCO.BO has a market cap of 100.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while OTCO.BO trades at ₹7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas OTCO.BO's P/E ratio is 389.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to OTCO.BO's ROE of -0.09%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to OTCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check OTCO.BO's competition here
AMRAPLIN.BO vs IFINSER.BO Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, IFINSER.BO has a market cap of 96.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while IFINSER.BO trades at ₹13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas IFINSER.BO's P/E ratio is 2.75. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to IFINSER.BO's ROE of +0.11%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IFINSER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IFINSER.BO's competition here
AMRAPLIN.BO vs MELSTAR.NS Comparison June 2026
AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRAPLIN.BO stands at 2.2B. In comparison, MELSTAR.NS has a market cap of 71.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹42.31, while MELSTAR.NS trades at ₹4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRAPLIN.BO currently has a P/E ratio of 17.27, whereas MELSTAR.NS's P/E ratio is 0.01. In terms of profitability, AMRAPLIN.BO's ROE is +0.34%, compared to MELSTAR.NS's ROE of -0.39%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MELSTAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MELSTAR.NS's competition here